KHSC, KGHRI and Queen’s research teams target causes, effects and treatments for COVID-19
Modifying existing antiviral drugs for better outcomes and revealing the mechanisms of a mysterious blood clotting syndrome are among six new COVID-19 research projects being pursued by researchers and clinician scientists at Kingston Health Sciences Centre, Kingston General Health Research Institute, and Queen’s University. The research is supported by funding totalling $670,000 from the Southeastern Ontario Academic Medical Organization (SEAMO).
“These researchers are recognized as leaders and innovators in their respective fields, and their work has the potential to significantly advance global understanding of this complex and perplexing disease,” says Dr. Steve Smith, Vice-Dean Research, Faculty of Heath Sciences, Queen’s, Vice President, Health Sciences Research, KHSC and President & CEO, KGHRI.
Stephen Archer & Victor Snieckus - Synthesis and preclinical testing of novel small molecule therapies for COVID-19
Currently no drugs have been proven effective in randomized clinical trials for treating the severe respiratory effects of COVID-19. Drs. Archer (Medicine) and Snieckus (Chemistry) are confronting this challenge on two fronts. They will modify existing antiviral drugs to improve their metabolism and efficiency, and reduce their toxic side effects. On a second front they have identified that SARS-CoV-2 kills cells, and may impair oxygen sensing by damaging mitochondria in lung cells. They will explore a novel mitochondrial pathway to combat the “happy hypoxemia” (low oxygen without appropriate shortness of breath), which characterizes COVID-19 pneumonia, and to prevent cell death by protecting mitochondria from SARS-CoV-2. Sussex Research Inc. (Ottawa) is collaborating in the antiviral drug synthetic work and dissemination of the results.
Paula James and David Lillicrap - Coagulopathy: Understanding and Treating a Novel Entity
Drs. James (Medicine) and Lillicrap (Pathology and Molecular Medicine), leading researchers in clinical and molecular hemostasis, are studying the links between COVID-19 coagulopathy, an unexplained and potentially fatal blood-clotting syndrome associated with SARS-CoV-2, and von Willebrand Factor (VWF), a blood clotting protein. They are collaborating with researchers at St. Michael’s Hospital (Toronto) and Vermont Medical Center who are studying the effects of the blood thinner heparin on COVID-19 patients, which has been shown in preliminary research to help these patients. The role of VWF in this disorder has not yet been studied, and the KHSC and KGHRI researchers aim to gain better understanding of the mechanisms of VWF in COVID-19 Coagulopathy, potentially leading to the development of new treatments.
David Maslove and Michael Rauh - COVID-19 and the Genetics of Mortality in Critical Care (GenOMICC)
Drs. Maslove (Critical Care) and Rauh (Pathology and Molecular Medicine) are part of an international genetics study on why some patients are affected more severely by COVID-19 than others. They will be looking at the genomes of patients admitted to intensive care units across Ontario and compare them to those of a healthy control population. Using advanced computing, they will be able to look at hundreds of thousands of subtle genetic variations across the population, to determine which of these are associated with outcomes. Knowing more about these variations will lead to new strategies for fighting the virus.
Martin Petkovich, Jacob Rullo & Martin tenHove - Coronavirus infection of the ocular mucosa to model infection and systemic immunity
Drs. ten Hove (Ophthalmology), Rullo (Ophthalmology), and Petkovich (Biomedical & Molecular Sciences) are studying local and systemic immune responses to SARS-CoV-2 infection using a physiological model that will examine how the virus infects the mucosal layer of the eyes. They will also determine the efficacy of administering a vaccination via this route to see if it generates systemic immunity against coronaviruses, and then use these results to study how the disease progresses in vaccinated and non-vaccinated models.
Robert Siemens & Charles Graham - The Role of BCG-induced innate immune memory in the protection against coronavirus
Countries that use the vaccine Bacillus Calmette Guerin (BCG) to prevent tuberculosis show lower rates of coronavirus infection than those that do not. Intriguingly, this vaccine has also been used to successfully treat bladder cancer. Drs. Siemens (Urology) and Graham (Biomedical & Molecular Sciences) believe that BCG enhances the body’s innate immune system. Their research aims to understand the immune-system mechanisms that lead to these protective benefits, and whether this vaccine could be used to protect against SARS-CoV-2, the coronavirus that causes COVID-19.
Dr. Stephen Vanner & Dr. Prameet Sheth - The application of metabolomics to enhance detection of COVID-19 and predict disease severity: A proof-of-principle study
Drs. Vanner (Gastrointestinal Diseases Research Unit) and Sheth (Pathology and Molecular Medicine) will use specialized mass spectrometry to study the metabolites found in nasopharyngeal samples of COVID-19. Their aim is to identify the unique signature of these tiny molecules, compared to other causes of respiratory infections such as the common cold. This metabolomic signature holds promise as a more sensitive, rapid and accurate identifier and predictor of the severity of the disease than current methods. It will also enable future studies on COVID-19 detection, prediction of disease severity, and virus identification in asymptomatic individuals.